Quantcast

Latest autoimmune diseases Stories

2014-07-10 10:20:50

University of Rochester Medical Center URMC-led study offers hope for atopic dermatitis sufferers An investigational medication shows promise in treating the most common skin disorder, often referred to as eczema or atopic dermatitis, according to a study published July 9 in the New England Journal of Medicine. The findings could eventually bring significant relief for many who suffer intense itching and other troubling features of atopic dermatitis, according to the study's lead...

2014-07-08 12:28:28

Strengthens Collaboration between the Nation's Lupus Research Organizations NEW YORK, July 8, 2014 /PRNewswire/ -- The Lupus Research Institute (LRI) today announced that Team Life Without Lupus(®) is joining the Alliance for Lupus Research (ALR) fundraising program Walk with Us to Cure Lupus in New York City to help raise funds for lupus research. To that end, 100% of all funds raised by LRI's Team Life Without Lupus will go towards lupus research. The LRI and ALR are...

2014-07-07 23:05:55

The Autoimmunity Bible & Norton Protocol is a new product created by Julia Liu and is a system designed for people suffering from and wanting to cure for good their autoimmune disorders. A complete review on the site Vinamy.com points out whether or not this program is effective. Seattle, WA (PRWEB) July 07, 2014 One of the last remaining mysteries know to modern medicine is the presence of the autoimmune disease, a blanket term applied for specific ailments which are caused by a...

2014-07-07 16:02:23

European League Against Rheumatism Low dosing of infliximab does not appear to alter treatment response or adherence Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit. Further data revealed that, in the case of the TNFα inhibitor...

2014-07-07 11:39:51

European League Against Rheumatism Slower dose tapering and absence of positive serology reduce risk of flare A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that, for the majority of lupus patients who are in remission, it is possible to successfully stop immunosuppressant therapy without triggering a flare of their disease. Within two years, it was possible to stop the immunosuppressant in about 70% of clinically stable...

early celiac sign
2014-07-04 03:30:55

NIH/National Institute of Diabetes and Digestive and Kidney Diseases NIH-funded study finds higher celiac risk in Sweden than US, elsewhere More than one quarter of children with two copies of a high-risk variant in a specific group of genes develop an early sign of celiac disease called celiac disease autoimmunity (CDA) by age 5. The findings are from The Environmental Determinants of Diabetes in Youth consortium, or TEDDY. The National Institutes of Health-funded study, published July...

2014-07-03 23:08:35

World Vitiligo Day 2014 promises to be the biggest yet, with a vast array of awareness and support events spanning the globe. Sponsored by the New York based Vitiligo Research Foundation, this years festivities will be based in Chandigarh, India. New York City, Now York (PRWEB) July 03, 2014 World Vitiligo Day day was Inaugurated in 2011 as a grassroots advocacy project to bring the plight of the approximately 100 million sufferers worldwide into the spotlight. As perhaps the world most...

2014-07-03 08:23:49

MUMBAI,India, July 3, 2014 /PRNewswire/ -- - GBR 830 is an antagonistic monoclonal antibody with first in class potential for the treatment of autoimmune diseases targeting OX40, a co-stimulatory receptor on T cells - The antibody has successfully completed the Phase I enabling preclinical development program and a Phase I clinical trial application has been filed with The Netherlands authorities -...

2014-07-03 08:23:24

- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical leader (Euronext: UCB), and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia(®) (certolizumab pegol) in dermatology. This collaboration aims...

2014-07-03 04:21:19

VIENNA, July 3, 2014 /PRNewswire/ -- Debilitating daily symptoms of Inflammatory Bowel Disease (IBD) not only cause depression and psychological complications in young people, but also significantly disrupts their education and ability to stay at work. In response to a new study highlighting the impact of IBD on children, United European Gastroenterology (UEG), Europe's largest digestive health body, is calling for quicker diagnosis and treatment to minimise the impact IBD has...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related